Spyre Therapeutics, Inc. (SYRE) Stock Analysis
Healthcare · Biotechnology · NasdaqGS
Spyre Therapeutics, Inc. (SYRE) posted $0 in revenue for fiscal 2025, with a net loss of $155.20M, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. has grown revenue from $4.63M to $0 over the last 10 fiscal years.
Synthesised from Spyre Therapeutics, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
Spyre Therapeutics, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.63M | $5.21M | $3.89M | $0 | $0 | $18.74M | $2.33M | $886,000 | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $-21.70M | $-27.24M | $-44.35M | $-78.25M | $-80.89M | $-65.80M | $-83.81M | $-338.79M | $-208.02M | $-155.20M |
| Net margin | -468.8% | -523.3% | -1140.6% | — | — | -351.1% | -3598.8% | -38238.1% | — | — |
Source: Spyre Therapeutics, Inc. SEC filings (10-K). 12 years of history available in the interactive view.
Spyre Therapeutics, Inc.: no obvious red flags in the filings
Our deterministic scan of the filed statements — receivables vs sales, earnings vs cash, dilution, leverage and margins — didn't flag anything. Ask about the risks →
Explore 12 years of Spyre Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track SYRE in your portfolio →
Spyre Therapeutics, Inc. financial history by metric
About Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Spyre Therapeutics, Inc. — frequently asked questions
What is Spyre Therapeutics, Inc.'s revenue?
Spyre Therapeutics, Inc. (SYRE) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Spyre Therapeutics, Inc. profitable?
No — SYRE reported a net loss of $-155.20M in fiscal 2025.
What is SYRE's P/E ratio?
Spyre Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Spyre Therapeutics, Inc. have?
As of fiscal year 2025, SYRE carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Spyre Therapeutics, Inc.'s market cap?
Spyre Therapeutics, Inc. (SYRE) has a market capitalization of about $6.84B, based on the latest data in our nightly-refreshed cache.
When does Spyre Therapeutics, Inc.'s fiscal year end?
SYRE's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Spyre Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 12 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.